xCELLigence RTCA Cardio by ACEA Biosciences – A part of Agilent

Manufacturer ACEA Biosciences – A part of Agilent  |  Available Worldwide
4.7
/
5.0
  |  3 reviews
Cardiomyocyte contractility and viability measured in real-time. The xCELLigence® RTCA Cardio instrument expands upon ACEA’s microelectronic-based cellular assay systems to enable monitoring of cardiomyocyte beating for cardiotoxicity assessment.  While it is similar to our other xCELLigence instruments in its use of noninvasive electrical impedance monitoring to asses cellular morphology change and attachment quality in a label-free and real-time manner, the Cardio model has a higher rate of... Read more


xCELLigence RTCA Cardio by ACEA Biosciences – A part of Agilent product image
xCELLigence RTCA Cardio
Request Pricing

Receive your quote directly from the manufacturer.




Average Rating: 4.7
3 Scientists have reviewed this product

5 out of 5
Ease of use
5 out of 5
After sales service
4 out of 5
Value for money


  • Status:

    Reviewer
  • Member since: 2016

  • Organization: University of Pittsburgh



  • Ease of use
    5 out of 5
    After sales service
    5 out of 5
    Value for money
    5 out of 5
This instrument is very useful
Rating: 5.0

  • Application Area: Analyzed cardiomyocytes beating rhythm

"I used this instrument to analyze human iPS cell derived cardiomyocytes beating rhythm. This instrument can give you reproducible results if you seed a certain number of cardiomyocytes every time, and the cardiomyocytes quality is stable. The advantage of this instrument is that it can collect real-time data for hours and days, especially if you need to perform drug treatment, it's easy to compare before and after drug treatment. Besides, the software is easy to use."

Review date: 11 Jul 2016 | xCELLigence RTCA Cardio
  • Status:

    Reviewer

  • Member since: 2015

  • Organization: University of Cologne



  • Ease of use
    5 out of 5
    After sales service
    4 out of 5
    Value for money
    3 out of 5
Rating: 4.0

  • Application Area:Cardiac function and Assessment of drug effects on cardiac cells activities

"Ease of Use because it is Label-free, real-time assessment platform, short and long term observations, precise system with ~1 ms resolution. Ease export and data analysis After Sales Care: Easy to manage Value for Money: Expensive for developing country researchers "

Review date: 02 Jul 2015 | xCELLigence RTCA Cardio
  • Status:

    Reviewer

  • Member since: 2015

  • Organization: AstraZeneca



  • Ease of use
    5 out of 5
    After sales service
    5 out of 5
    Value for money
    5 out of 5
Rating: 5.0

  • Application Area:kinase inhibitor cardiotoxicity

"The xCELLigence has provided extremely robust data with experiments I have conducted looking at effects of compounds as well as effect of gene knockdown on CM beating. Technical support staff have always been extremely quick to answer and helpful with any questions I have had. "

Review date: 30 Jun 2015 | xCELLigence RTCA Cardio

Cardiomyocyte contractility and viability measured in real-time.

The xCELLigence® RTCA Cardio instrument expands upon ACEA’s microelectronic-based cellular assay systems to enable monitoring of cardiomyocyte beating for cardiotoxicity assessment.  While it is similar to our other xCELLigence instruments in its use of noninvasive electrical impedance monitoring to asses cellular morphology change and attachment quality in a label-free and real-time manner, the Cardio model has a higher rate of data acquisition (every 12.9 milliseconds).  Because cell-induced electrical impedance is dependent on cell size/shape and how strongly the cell interacts with the plate bottom, the contraction-relaxation cycle of cardiomyocytes gives rise to a distinct, rhythmic fluctuation in impedance that is readily captured on the millisecond time scale.  Changes in the intensity and periodicity of this “beating” pattern can be monitored in the short (seconds) to long (days) time regimes to assess cardiomyocyte contractility and viability in the presence of different drugs.  This enables the evaluation of both short-term and long-term (chronic exposure or repeat dosing) cardiotoxicity for clinical safety testing under conditions that are maximally physiologically relevant.

The xCELLigence RTCA Cardio instrument, which analyzes cells in an electronic 96-well microtiter plate format (E-Plate® Cardio 96), is placed in a standard CO2 cell culture incubator and interfaces via a cable with analysis and control units that are housed outside the incubator.  User friendly software allows for real-time control and monitoring of the instrument, and includes real-time data display and analysis functions that provide quantitative information about the health of the cells, including viability and beating activity/irregularity.

The analysis of human iPSC-derived cardiomyocytes with the xCELLigence RTCA Cardio instrument has proven to be an extremely accurate, highly predictive in vitro assay for assessing drug-induced cardiac liability.  Since 2010, more than 20 such studies have been published. The results collectively show that the xCELLigence RTCA Cardio system addresses previously unmet needs in in vitro cardio safety screening by:

  • Being a high-throughput method for detecting functional cardiotoxicity (effects on short-term and long-term cardio beating activity) and general toxicity in vitro
  • Having good correlation with clinical arrhythmogenic risk
  • Providing insight into compound mechanism of action

Product Overview

xCELLigence RTCA Cardio by ACEA Biosciences – A part of Agilent product image

xCELLigence RTCA Cardio

Manufacturer ACEA Biosciences – A part of Agilent  |  Available Worldwide

4.7 / 5.0 | 3 reviews